Publication

89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment

Oosting, S. F., Brouwers, A. H., van Es, S. C., Nagengast, W. B., Oude Munnink, T. H., Lub-de Hooge, M. N., Hollema, H., de Jong, J. R., de Jong, I. J., de Haas, S., Scherer, S. J., Sluiter, W. J., Dierckx, R. A., Bongaerts, A. H. H., Gietema, J. A. & de Vries, E. G. E., Jan-2015, In : Journal of Nuclear Medicine. 56, 1, p. 63-69 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Oosting, S. F., Brouwers, A. H., van Es, S. C., Nagengast, W. B., Oude Munnink, T. H., Lub-de Hooge, M. N., Hollema, H., de Jong, J. R., de Jong, I. J., de Haas, S., Scherer, S. J., Sluiter, W. J., Dierckx, R. A., Bongaerts, A. H. H., Gietema, J. A., & de Vries, E. G. E. (2015). 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. Journal of Nuclear Medicine, 56(1), 63-69. https://doi.org/10.2967/jnumed.114.144840

Author

Oosting, Sjoukje F ; Brouwers, Adrienne H ; van Es, Suzanne C ; Nagengast, Wouter B ; Oude Munnink, Thijs H ; Lub-de Hooge, Marjolijn N ; Hollema, Harry ; de Jong, Johan R ; de Jong, Igle J ; de Haas, Sanne ; Scherer, Stefan J ; Sluiter, Wim J. ; Dierckx, Rudi A ; Bongaerts, Alfons H H ; Gietema, Jourik A ; de Vries, Elisabeth G E. / 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. In: Journal of Nuclear Medicine. 2015 ; Vol. 56, No. 1. pp. 63-69.

Harvard

Oosting, SF, Brouwers, AH, van Es, SC, Nagengast, WB, Oude Munnink, TH, Lub-de Hooge, MN, Hollema, H, de Jong, JR, de Jong, IJ, de Haas, S, Scherer, SJ, Sluiter, WJ, Dierckx, RA, Bongaerts, AHH, Gietema, JA & de Vries, EGE 2015, '89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment', Journal of Nuclear Medicine, vol. 56, no. 1, pp. 63-69. https://doi.org/10.2967/jnumed.114.144840

Standard

89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. / Oosting, Sjoukje F; Brouwers, Adrienne H; van Es, Suzanne C; Nagengast, Wouter B; Oude Munnink, Thijs H; Lub-de Hooge, Marjolijn N; Hollema, Harry; de Jong, Johan R; de Jong, Igle J; de Haas, Sanne; Scherer, Stefan J; Sluiter, Wim J.; Dierckx, Rudi A; Bongaerts, Alfons H H; Gietema, Jourik A; de Vries, Elisabeth G E.

In: Journal of Nuclear Medicine, Vol. 56, No. 1, 01.2015, p. 63-69.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN et al. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. Journal of Nuclear Medicine. 2015 Jan;56(1):63-69. https://doi.org/10.2967/jnumed.114.144840


BibTeX

@article{800d2965ae824494a9d5f923126019da,
title = "89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment",
abstract = "UNLABELLED: No validated predictive biomarkers for antiangiogenic treatment of metastatic renal cell carcinoma (mRCC) exist. Tumor vascular endothelial growth factor A (VEGF-A) level may be useful. We determined tumor uptake of (89)Zr-bevacizumab, a VEGF-A-binding PET tracer, in mRCC patients before and during antiangiogenic treatment in a pilot study.METHODS: Patients underwent (89)Zr-bevacizumab PET scans at baseline and 2 and 6 wk after initiating either bevacizumab (10 mg/kg every 2 wk) with interferon-α (3-9 million IU 3 times/wk) (n = 11) or sunitinib (50 mg daily, 4 of every 6 wk) (n = 11). Standardized uptake values were compared with plasma VEGF-A and time to disease progression.RESULTS: (89)Zr-bevacizumab PET scans visualized 125 evaluable tumor lesions in 22 patients, with a median SUV(max) (maximum standardized uptake value) of 6.9 (range, 2.3-46.9). Bevacizumab/interferon-α induced a mean change in tumor SUV(max) of -47.0% (range, -84.7 to +20.0%; P < 0.0001) at 2 wk and an additional -9.7% (range, -44.8 to +38.9%; P = 0.015) at 6 wk. In the sunitinib group, the mean change in tumor SUV(max) was -14.3% at 2 wk (range, -80.4 to +269.9; P = 0.006), but at 6 wk the mean change in tumor SUV(max) was +72.6% (range, -46.4 to +236%; P < 0.0001) above baseline. SUV(max) was not related to plasma VEGF-A at all scan moments. A baseline mean tumor SUV(max) greater than 10.0 in the 3 most intense lesions corresponded with longer time to disease progression (89.7 vs. 23.0 wk; hazard ratio, 0.22; 95% confidence interval, 0.05-1.00).CONCLUSION: Tumor uptake of (89)Zr-bevacizumab is high in mRCC, with remarkable interpatient and intrapatient heterogeneity. Bevacizumab/interferon-α strongly decreases tumor uptake whereas sunitinib results in a modest reduction with an overshoot after 2 drug-free weeks. High baseline tumor SUV(max) was associated with longer time to progression.",
keywords = "renal cell carcinoma, molecular imaging, positron emission tomography, bevacizumab, sunitinib, ENDOTHELIAL GROWTH-FACTOR, METASTATIC BREAST-CANCER, PHASE-III TRIAL, INTERFERON-ALPHA, ANTI-VEGF, BEVACIZUMAB, SUNITINIB, EFFICACY, IN-111-BEVACIZUMAB, BIODISTRIBUTION",
author = "Oosting, {Sjoukje F} and Brouwers, {Adrienne H} and {van Es}, {Suzanne C} and Nagengast, {Wouter B} and {Oude Munnink}, {Thijs H} and {Lub-de Hooge}, {Marjolijn N} and Harry Hollema and {de Jong}, {Johan R} and {de Jong}, {Igle J} and {de Haas}, Sanne and Scherer, {Stefan J} and Sluiter, {Wim J.} and Dierckx, {Rudi A} and Bongaerts, {Alfons H H} and Gietema, {Jourik A} and {de Vries}, {Elisabeth G E}",
note = "{\textcopyright} 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.",
year = "2015",
month = jan,
doi = "10.2967/jnumed.114.144840",
language = "English",
volume = "56",
pages = "63--69",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "SOC NUCLEAR MEDICINE INC",
number = "1",

}

RIS

TY - JOUR

T1 - 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment

AU - Oosting, Sjoukje F

AU - Brouwers, Adrienne H

AU - van Es, Suzanne C

AU - Nagengast, Wouter B

AU - Oude Munnink, Thijs H

AU - Lub-de Hooge, Marjolijn N

AU - Hollema, Harry

AU - de Jong, Johan R

AU - de Jong, Igle J

AU - de Haas, Sanne

AU - Scherer, Stefan J

AU - Sluiter, Wim J.

AU - Dierckx, Rudi A

AU - Bongaerts, Alfons H H

AU - Gietema, Jourik A

AU - de Vries, Elisabeth G E

N1 - © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

PY - 2015/1

Y1 - 2015/1

N2 - UNLABELLED: No validated predictive biomarkers for antiangiogenic treatment of metastatic renal cell carcinoma (mRCC) exist. Tumor vascular endothelial growth factor A (VEGF-A) level may be useful. We determined tumor uptake of (89)Zr-bevacizumab, a VEGF-A-binding PET tracer, in mRCC patients before and during antiangiogenic treatment in a pilot study.METHODS: Patients underwent (89)Zr-bevacizumab PET scans at baseline and 2 and 6 wk after initiating either bevacizumab (10 mg/kg every 2 wk) with interferon-α (3-9 million IU 3 times/wk) (n = 11) or sunitinib (50 mg daily, 4 of every 6 wk) (n = 11). Standardized uptake values were compared with plasma VEGF-A and time to disease progression.RESULTS: (89)Zr-bevacizumab PET scans visualized 125 evaluable tumor lesions in 22 patients, with a median SUV(max) (maximum standardized uptake value) of 6.9 (range, 2.3-46.9). Bevacizumab/interferon-α induced a mean change in tumor SUV(max) of -47.0% (range, -84.7 to +20.0%; P < 0.0001) at 2 wk and an additional -9.7% (range, -44.8 to +38.9%; P = 0.015) at 6 wk. In the sunitinib group, the mean change in tumor SUV(max) was -14.3% at 2 wk (range, -80.4 to +269.9; P = 0.006), but at 6 wk the mean change in tumor SUV(max) was +72.6% (range, -46.4 to +236%; P < 0.0001) above baseline. SUV(max) was not related to plasma VEGF-A at all scan moments. A baseline mean tumor SUV(max) greater than 10.0 in the 3 most intense lesions corresponded with longer time to disease progression (89.7 vs. 23.0 wk; hazard ratio, 0.22; 95% confidence interval, 0.05-1.00).CONCLUSION: Tumor uptake of (89)Zr-bevacizumab is high in mRCC, with remarkable interpatient and intrapatient heterogeneity. Bevacizumab/interferon-α strongly decreases tumor uptake whereas sunitinib results in a modest reduction with an overshoot after 2 drug-free weeks. High baseline tumor SUV(max) was associated with longer time to progression.

AB - UNLABELLED: No validated predictive biomarkers for antiangiogenic treatment of metastatic renal cell carcinoma (mRCC) exist. Tumor vascular endothelial growth factor A (VEGF-A) level may be useful. We determined tumor uptake of (89)Zr-bevacizumab, a VEGF-A-binding PET tracer, in mRCC patients before and during antiangiogenic treatment in a pilot study.METHODS: Patients underwent (89)Zr-bevacizumab PET scans at baseline and 2 and 6 wk after initiating either bevacizumab (10 mg/kg every 2 wk) with interferon-α (3-9 million IU 3 times/wk) (n = 11) or sunitinib (50 mg daily, 4 of every 6 wk) (n = 11). Standardized uptake values were compared with plasma VEGF-A and time to disease progression.RESULTS: (89)Zr-bevacizumab PET scans visualized 125 evaluable tumor lesions in 22 patients, with a median SUV(max) (maximum standardized uptake value) of 6.9 (range, 2.3-46.9). Bevacizumab/interferon-α induced a mean change in tumor SUV(max) of -47.0% (range, -84.7 to +20.0%; P < 0.0001) at 2 wk and an additional -9.7% (range, -44.8 to +38.9%; P = 0.015) at 6 wk. In the sunitinib group, the mean change in tumor SUV(max) was -14.3% at 2 wk (range, -80.4 to +269.9; P = 0.006), but at 6 wk the mean change in tumor SUV(max) was +72.6% (range, -46.4 to +236%; P < 0.0001) above baseline. SUV(max) was not related to plasma VEGF-A at all scan moments. A baseline mean tumor SUV(max) greater than 10.0 in the 3 most intense lesions corresponded with longer time to disease progression (89.7 vs. 23.0 wk; hazard ratio, 0.22; 95% confidence interval, 0.05-1.00).CONCLUSION: Tumor uptake of (89)Zr-bevacizumab is high in mRCC, with remarkable interpatient and intrapatient heterogeneity. Bevacizumab/interferon-α strongly decreases tumor uptake whereas sunitinib results in a modest reduction with an overshoot after 2 drug-free weeks. High baseline tumor SUV(max) was associated with longer time to progression.

KW - renal cell carcinoma

KW - molecular imaging

KW - positron emission tomography

KW - bevacizumab

KW - sunitinib

KW - ENDOTHELIAL GROWTH-FACTOR

KW - METASTATIC BREAST-CANCER

KW - PHASE-III TRIAL

KW - INTERFERON-ALPHA

KW - ANTI-VEGF

KW - BEVACIZUMAB

KW - SUNITINIB

KW - EFFICACY

KW - IN-111-BEVACIZUMAB

KW - BIODISTRIBUTION

U2 - 10.2967/jnumed.114.144840

DO - 10.2967/jnumed.114.144840

M3 - Article

C2 - 25476536

VL - 56

SP - 63

EP - 69

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 1

ER -

ID: 16223735